Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lir Life SciencesFRA:N790 +31.30%15 Piotroski F-Score is 3 as of Sep. 05, 2026. GuruFocus rates FRA:N790 with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 1,341 Biotechnology companies, Lir Life Sciences ranks worse than 74571.14% on this metric.
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Lir Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Lir Life Sciences's Piotroski F-Score or its related term are showing as below:
FRA:N790'
s Piotroski F-Score Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3
Current: 3
During the past 3 years, the highest Piotroski F-Score of Lir Life Sciences was 3. The lowest was 0. And the median was 0.
Lir Life Sciences (FRA:N790) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Lir Life Sciences Piotroski F-Score Related Terms
Lir Life Sciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:N790 vs VRTX, REGN, MRNA: Piotroski F-Score Comparison
For the Biotechnology subindustry, Lir Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Lir Life Sciences's current Net Income (TTM) was -2.33.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Lir Life Sciences's return on assets of this year was -30.31168831. Lir Life Sciences's return on assets of last year was -3.62142857.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Lir Life Sciences's gearing of this year was 0. Lir Life Sciences's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Lir Life Sciences's current ratio of this year was 4.64285714. Lir Life Sciences's current ratio of last year was 0.59689922.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Lir Life Sciences's number of shares in issue this year was 28.209. Lir Life Sciences's number of shares in issue last year was 27.867.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Lir Life Sciences's gross margin of this year was . Lir Life Sciences's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Lir Life Sciences's asset turnover of this year was 0. Lir Life Sciences's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
1
+
1
+
0
+
0
+
0
=
3
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Lir Life Sciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
Lir Life Sciences (FRA:N790) has a Piotroski F-Score of 3 as of Sep. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 1341 companies in the Biotechnology industry.
Is Lir Life Sciences' Piotroski F-Score too high?
Lir Life Sciences' current Piotroski F-Score is 3. The Biotechnology industry median Piotroski F-Score is 3.00. Lir Life Sciences' value of 3 is 0% at this industry median. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 1341 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 1341 companies for Piotroski F-Score. This places Lir Life Sciences in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Lir Life Sciences' value of 3 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Piotroski F-Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (FRA:N790) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3 and 0% at the Biotechnology industry median of 3.00. Lir Life Sciences' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Lir Life Sciences (FRA:N790), the current Piotroski F-Score is 3 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for FRA:N790
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N790 has been successfully added to your 
